Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Einsele H, Engelhardt M, Tapprich C, Mueller J, Liebisch P, Langer C, Kropff M, Muegge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jaeger E, Bentz M, Duerk HA, Salwender H, Hebart H, Straka C, Knop S (2017)


Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 179

Pages Range: 586-597

Journal Issue: 4

DOI: 10.1111/bjh.14920

Abstract

We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade >=3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator-based assessment was 85·4%. Most patients (74%) underwent successful central laboratory-based molecular cytogenetic analysis. No clinically relevant differences in ORR post-induction were seen between patients with or without high-risk cytogenetic abnormalities (86·2% vs. 84·3%). Further follow-up data are available for 113 patients receiving ASCT who were included in a prospective consolidation trial (median follow-up, 55·5 months); median progression-free survival (PFS) was 35·3 months and median overall survival (OS) was not reached. In patients with high-risk versus standard-risk cytogenetics, median PFS was 19·9 vs. 43·6 months (P < 0·0001), and median OS was 54·7 months versus not reached (P = 0·0022). VCD is an effective and tolerable induction regimen; results suggest that VCD induces high response rates independently of cytogenetic risk status, but after long-term follow-up, cytogenetic high risk is associated with markedly reduced PFS and OS post-ASCT.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Einsele, H., Engelhardt, M., Tapprich, C., Mueller, J., Liebisch, P., Langer, C.,... Knop, S. (2017). Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. British Journal of Haematology, 179(4), 586-597. https://dx.doi.org/10.1111/bjh.14920

MLA:

Einsele, Hermann, et al. "Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial." British Journal of Haematology 179.4 (2017): 586-597.

BibTeX: Download